HCPCS Level II · Drugs administered other than oral method
J1330Injection, ergonovine maleate, up to 0.2 mg
Terminated 12/31/2025
Source: CMS HCPCS quarterly update, October 2026. Page updated September 29, 2026.
About J1330
J1330 is an HCPCS Level II code in the J series (drugs administered other than oral method), describing injection, ergonovine maleate, up to 0.2 mg.
It was added to HCPCS effective 01/01/1986, and its current record took effect 01/01/2026.
It was terminated on 12/31/2025 and can't be billed for later dates of service.
Its Medicare coverage code is "D", meaning special Medicare coverage instructions apply.
Details
- Short description
- Ergonovine maleate injection
- Date added
- 01/01/1986
- Action effective
- 01/01/2026
- Termination date
- 12/31/2025
- BETOS
- O1E
Related J13xx codes
- J1301Injection, edaravone, 1 mg
- J1302Injection, sutimlimab-jome, 10 mg
- J1303Injection, ravulizumab-cwvz, 10 mg
- J1304Injection, tofersen, 1 mg
- J1305Injection, evinacumab-dgnb, 5mg
- J1306Injection, inclisiran, 1 mg
- J1307Injection, crovalimab-akkz, 10 mg
- J1308Injection, famotidine, 0.25 mg
- J1320Injection, amitriptyline hcl, up to 20 mg
- J1322Injection, elosulfase alfa, 1 mg
- J1323Injection, elranatamab-bcmm, 1 mg
- J1324Injection, enfuvirtide, 1 mg
Common questions about J1330
Is HCPCS J1330 still valid?
- No. J1330 was terminated on 12/31/2025.
Does Medicare cover J1330?
- Its coverage code is "D": special Medicare coverage instructions apply. Check the local coverage determination for your region.